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The ability to manipulate the activity of interneurons with optogenetic tools offers the possibility to 
interfere with diseases caused by altered neuronal inhibition and synchrony, including epilepsy and
schizophrenia. To develop vectors for therapeutic approaches, targeting optogenetic constructs to 
interneurons is therefore a key requirement. We asked if the interneuron-specific promoters 
glutamic acid decarboxylase (GAD)67 and cholecystokinin (CCK) allowed targeted lentiviral 
delivery of opsins to interneurons as a whole, or specifically CCK-positive(+) interneurons. 
Methods 
We generated lentiviral (LV) plasmids encoding channelrhodopsin (ChR2) and halorhodopsin 
(NpHR) tagged with fluorophores and driven by GAD67 or CCK promoters. Adeno-associated virus
(AAV) and LV vectors carrying opsins driven by pyramidal cell promoters were used as controls. 
We transduced neuronal cultures and rodent brain in vivo, immunostained specimens 6-8 weeks 
following in vivo injection, 7-14 days after in vitro transduction, and evaluated volume and 
specificity of expression by confocal microscopy. 
Results 
In vitro 90% (19/21) of LV-CCK-NpHR2.0-EYFP expressing neurons were CCK+. In vivo LV-
GAD67-ChR2-mCherry was expressed in 2.6%(5/193), LV-GAD67-NpHR2.0-EYFP in 
~15%(43/279), LV-CCK-NpHR2.0-EYFP in 47%(9/19) of hippocampal GABA+ interneurons. 
GAD67 vectors expressed in larger volumes than CCK-driven constructs, AAV vector controls 
achieved the largest expression volumes. 
Conclusions 
LV-CCK-NpHR2.0-EYFP may be useful to target CCK+ interneurons in culture. GAD67/CCK-
driven lentiviral constructs are expressed in vivo, but expression is not specific for interneurons. 
Overall, expression levels are low compared to opsins driven by pyramidal cell promoters. Better 
understanding of GAD67 and CCK promoter structure or alternative techniques are required to 
reliably target opsins to interneurons using viral vectors. 
1. Introduction
Optogenetic techniques [1,2] combine optical and genetic tools, and allow targeted optical control 
of firing in neurons through expression of opsins on neuronal cell membranes. Excessive or altered
neuronal synchrony underlies common nervous system diseases, such as epilepsy and 
schizophrenia [3]. As interneurons are responsible for timing and synchronizing pyramidal cell 
activity [4], and are known to prevent seizure spread [5], targeting opsins to these inhibitory cells is
key to influence interneuron function for therapeutic purposes. Augmenting interneuron activity or 
altering their firing patterns could be used as treatment tool, to interfere with epileptiform activity 
[6], or to re-synchronize oscillating neuronal ensembles in schizophrenia and Parkinson's disease, 
but also to dissect the roles of different subclasses of interneurons in various diseases of the 
nervous system [6,7]. 
Targeting interneurons in vitro and in vivo can be achieved by either using opsin-carrying 
neurotropic viral vectors, or transgenic models. In both cases, a cell-type specific promoter drives 
opsin expression. The advantage of using viral vectors is that they transduce a limited volume of 
tissue, which allows precise targeting of very specific areas of interest. A further advantage of viral 
vectors includes their potential translational applications, such as their use in human patients. To 
date, transcription of virally delivered genes in the nervous system has been achieved by either 
using strong but non-specific neuronal promoters (including synapsin-1 [8], elongation factor 1a 
(EF-1a) [9], neuron-specific enolase[10]), or by using weaker but more specific promoters such as 
calcium calmodulin-binding kinase 2a (Camk2a [11], specific for excitatory neurons) and glutamic 
acid decarboxylase 1 (Gad1, equivalent to GAD67 in mouse and specific for GABAergic 
interneurons as a whole [12]). Other cell-type specific promoters used are prepro-hypocretin (Hcrt, 
specific for hypocretin neurons [13]), glial fibrillary acidic protein (GFAP, specific for astrocytes 
[14]), tyrosine hydroxylase (for targeting catecholaminergic neurons [15]) and neurofilament [16]. 
An alternative technique to achieve expression of virally delivered genes in the nervous system 
consists of adding enhancing cassettes or intronic sequences to the transgene of interest [17, 18]. 
To understand how manipulation of inhibitory interneuron excitability alters pyramidal cell activity 
[19] and influences epileptic networks [20], we set out to investigate if targeted viral delivery of the 
two major opsins channelrhodopsin-2 (ChR2) and halorhodopsin (NpHR) to interneurons was 
feasible in vivo and in vitro. 
Very few mammalian promoters have been characterized sufficiently enough to allow viral 
expression of transgenes specific to interneurons: these include fragments of the GAD67 promoter 
to target γ-amino butyric acid (GABA)ergic interneurons as a whole [21, 22, 12], and 
cholecystokinin (CCK) [23, 24], to target a subset of CCK-expressing interneurons. In both cases 
these promoter sequences span over 3 kb. Whilst successful expression of fluorophores in 
interneurons has been reported using a GAD67 promoter-carrying adeno-associated virus (AAV) 
vectors [21, 22, 12], the remaining AAV payload is too small to also carry an opsin gene. 
Targeted expression of opsins to interneurons has so far only been achieved by injection of vector 
carrying a floxed-stop opsin construct into Cre-mice lines expressing Cre-recombinase under a 
promoter specific for interneurons. Examples include Cre-driver lines under the promoters 
parvalbumin (PV) and somatostation (SST), specific for subsets of GABAergic interneurons [25, 
26, 27, 6], and glutamic acid decarboxylase 2 (Gad2), specific for GABAergic interneurons as a 
whole [6]. 
We asked if a lentivirus (LV) vectors (LVV) incorporating the GAD67 or CCK-promoter could 
reliably target opsins to interneurons in wild-type tissue in vitro and in vivo. Targeting opsins to 
interneurons as a whole, or to CCK-positive interneurons, using lentiviral vectors has not been 
previously described. We chose to employ lentiviral constructs as they have a large transgene 
capacity of 8-10 kb, allowing them to carry the genes for promoter, opsin and fluorophore. A further
advantage considering future clinical applications is the lack of immune response to LVVs and the 
possibility of large scale production of clinical grade vectors. 
We were able to demonstrate that our opsin carrying lentiviral constructs driven by the interneuron-
specific promoters GAD67 and CCK are expressed in neuronal cultures and rat motor cortex and 
hippocampus. In cultures enriched in interneurons, such as those from the ganglionic eminence, 
LV-CCK-NpHR2.0-EYFP may be useful to target CCK+ interneurons. Expression levels in vivo, 
however, were low and expression was not specific for interneurons. Our results suggest that, in 
their current form, the two promoters may not contain all regulatory sequences necessary to target 
opsins to interneurons in cortex and hippocampus [21], or may indicate that LVVs are less suitable 
than other viral vectors to target inhibitory neurons [28]. 
2. Materials and Methods
Plasmid Design and Construction
Lentiviral plasmids used to target excitatory neurons contained NpHR2.0–EYFP (enhanced yellow 
fluorescent protein, EYFP) and hChR2(H134R)-mCherry under the excitatory neuron specific 
promoter Camk2a (gift of K.Deisseroth, Stanford University [11]). They were used as backbones to
generate the constructs carrying the GAD67 (gift of S. Kasparov [22]) and CCK promoters (gift of 
K. Ressler [23, 24]). The vectors have a truncated HIV 3'LTR, contain the HIV-1 central polypurine 
tract (cPPT) [29] and the Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element 
(WPRE) [30] to improve transduction efficiency. To construct the vectors pLenti-CCK-NpHR–EYFP
and pLenti-CCK-ChR2-mCherry, an XbaI site was inserted into pLenti-CCKpro-GFP (green 
fluorescent protein, GFP) by mutagenizing it with the following primers: forward 
5’-acaaaaacaaattacaaaaattcaaaattttatctagatttcccagggaagatgaagaa-3’ and 
reverse 5’-ttcttcatcttccctgggaaatctagataaaattttgaatttttgtaatttgtttttgt-3’. The ~3 kb CCK promoter 
sequence was subsequently removed (XbaI/BamHI fragment) and ligated into pLenti-Camk2a-
NpHR2.0–EYFP and pLenti-Camk2a-ChR2-mCherry cut with the restriction enzymes XbaI/BamHI. 
Plasmids were purified using conventional kits (Qiagen) and all sequences were confirmed by 
restriction enzyme digestion and sequencing. GAD67 subcloning was outsourced to Entechelon 
GmBH, Regensburg, Germany. The adenoviral vector (AVV) shuttle carrying 3.7 kb of GAD67 
promoter sequences was mutagenized and a PacI site inserted 5’-upstream of the PmlI site. The 
Camk2a promoter was subsequently removed from pLenti-Camk2a-NpHR2.0–EYFP and pLenti-
Camk2a-ChR2-mCherry via restriction digest with PacI/PmlI and the GAD67 promoter cloned in. 
Viral Production and Titration
VSVg pseudotyped lentiviral vectors were generated according to local protocols: 293FT cells 
(Invitrogen) were seeded 24 hours prior to transfection in order to reach 90% confluence the 
following day. Cells were co-transfected with the transfer vector, p8.91 (gag/pol expressor) and 
pMD.G (VSVg expressor) in Fugene 6 (Roche), Optimem and sterile Tris-
Ethylenediaminetetraacetic acid buffer (both Invitrogen), pH 8. LVV-containing supernatant was 
harvested approximately 24, 48 and 72 hours after transfection. LVV was concentrated by 
ultracentrifugation at 20,000 rpm for 2 hours at 4 °C in a swing-out rotor ultracentrifuge (Beckman 
Coulter). After centrifugation, the vector was re-suspended, aliquoted and stored long term at -80 
°C. The concentrated viral titer was determined by reverse transcriptase quantitative polymerase 
chain reaction (RT-qPCR) to be between 108 and 109  copies/ml. 
pAAV5-hSyn-eNpHR3.0-2A-ChR2-EYFP (AAV-eNPAC [31] serotype 5, purchased from UNC 
vector core, titres 1x1012 vector genome(vg)/ml), carrying a strong pan-neuronal promoter, and 
pLenti-Camk2a-NpHR2.0–EYFP/pLenti-Camk2a-ChR2-mCherry, carrying a promoter specific for 
excitatory neurons, were used as a control vectors for in vivo experiments. 
Viral Transduction in Vitro
Neuronal cultures from the medial ganglionic eminence (embryonal day 14) were a gift of W. 
Andrews  (J. Parnavelas laboratory, Department of Cell and Developmental Biology, UCL). Day 7 
neuronal cultures were transduced with serial dilutions of the LVV. Images were taken using a 
Leica Fluorescence microscope. Cultures were incubated at 37 °C for 7–14 days before fixation in 
4 % paraformaldehyde for subsequent immunofluorescence. 
Stereotactic Surgery and Viral Transduction in Vivo for Targeting Opsins to Interneurons 
Male postnatal day 20 (p20) Sprague-Dawley rats were used for in vivo viral vector injections. The 
correct coordinates for the hippocampal injection site were established through calibration 
experiments by injection of Trypan Blue into the target area. All animals were housed on a 12-hour 
light/dark cycle in a temperature- and humidity-controlled environment with free access to food and
water. All efforts were made to minimize animal suffering and to reduce the number of animals 
used. Animal experiments were conducted in accordance with the Animals (Scientific Procedures) 
Act 1986. 
For stereotactic injections each rat was anaesthetized with isoflurane (Forane; Abbot). Animals 
were placed in a stereotactic frame (Kopf instruments). Surgery was performed under a Leica S6E 
microscope. LVV was injected directly with a Hamilton syringe (5 µl Hamilton Syringe, 900 Series, 
liquid tight with reinforced plunger; 33 G blunt needle; injection rate 200 nl/min with a microinjector 
unit). Injection volume was of 1 µl to cortex at the following stereotaxic coordinates AP -1.5 , L -1.5,
V -1.45, and 1.5 µl to dorsal CA1/3 at AP -2.8 , L +3.6, V -2.9 and ventral CA3: AP -4.1, L +4.45, V 
+5.35. Before lightening anaesthesia, rats were injected with 0.05 mg/kg subcutaneous (s.c.) 
buprenorphine analgesia and 1–2 ml s.c. 0.9% saline and the animal allowed to recover. 
Tissue Processing 
Animals were sacrificed by an overdose of pentobarbitone up to 6–8 weeks following viral vector 
injection. For immunohistochemistry, rats were perfused transcardially with ice-cold artificial 
cerebrospinal fluid, decapitated and the brains removed and post-fixed for 24 h in 4% 
paraformaldehyde (PFA; adjusted to pH 7.4 with 1 M HCl) at 4°C. They were then transferred to a 
solution containing 30% sucrose in 1x phosphate buffered saline (PBS) and left at 4°C until they 
had sunk. Using a Leica freezing vibratome, 30 µm coronal sections were cut through the targeted 
brain regions. 
Immunohistochemistry
Immunohistochemical staining was conducted on free floating sections. Sections were washed in 
PBS and permeabilized in 0.2% Triton X-100 for 10 minutes and then blocked with DAKO-blocking 
medium (dako) for 1 hour on a shaker. Series of sections were incubated for 2 days in the primary 
antibodies against γ-amino butyric acid (GABA, 1:100-1:200, Thermo Scientific, PA1-18027), 
cholecystokinin-8 (CCK-8, 1:100-1:200, Thermo Scientific, PA1-18016), Camk2a (1:100-1:200, 
Thermo Scientific, #MA1-048), green-fluorescent protein (GFP, 1:3000, abcam, ab13970 or aves 
1:800), dsRed and mCherry (1:200, Living Colors®; DsRed or mCherry Monoclonal Antibody, 
catalogue no. 632392 and 632543). Following washing in PBS (3 x 15 min), the sections were 
incubated in secondary antibodies (1:1000, all abcam and labelled with Alexa Fluor (AF) 488, AF 
568 or Tetramethylrhodamine (kindly gifted by A. Cariboni and J. Parnavelas) overnight at 4°C. 
After further washing in PBS, sections were incubated in 4´,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) to visualize cell nuclei. Free-floating sections were mounted onto 
microscope slides, allowed to dry and then coverslipped using Mowiol Mounting Medium (gift of A. 
Cariboni and J. Parnavelas). The same protocol was used to stain cultured neurons. As fixation 
with 4% PFA greatly reduces the fluorescent signal, constructs carrying NpHR-EYFP were always 
stained with primary antibodies against EYFP and secondaries labelled with AF 488 to detect 
expression of the vector, constructs carrying ChR2-mCherry were counterstained with primaries 
against dsRed or mCherry and secondaries labelled with AF 561 or Tetramethylrhodamine. For 
colocalization studies, primary antibodies  against GABA, CCK and Camk2a were labelled with 
secondaries conjugated to a red fluorophore (for the NpHR-EYFP expressing slices) or a green 
fluorophore (for the ChR2-mCherry expressing slices). Slices from adult male GAD67-GFP mice 
expressing GFP in interneurons were used as positive controls for anti-GAD67, anti-CCK and anti-
Camk2a antibodies (Supplementary Fig. 1). 
Morphological Analysis
The evaluation and acquisition of morphological data were performed on a Leica DM2500 Upright 
confocal microscope with a 40x oil immersion objective and the following excitation laser lines: 488
nm, 532 nm, 405 nm. Slices were first analyzed by fluorescence microscopy for expression of the 
fluorochrome in the targeted area. Image acquisition was performed with Leica LAS AF software. 
The colocalization of opsin expressing cells and neuronal or glial cell markers (GABA, CCK, 
Camk2a) was analyzed in the cortex and hippocampus. To compare the extent of viral vector 
expression volumes of different constructs, the size of the area exhibiting EYFP fluorescence was 
measured at 5–10-fold magnification in the cortex and hippocampus. Volumetric analysis was 
performed using Octave open source analysis software. Immunostained sections were digitized by 
means of a high-resolution video camera. All stained sections were evaluated. Image analysis and 
cell counting was performed using GIMP (GNU Image Manipulation Program) and Image J open 
source software. 
3. Results
GAD67- and CCK-driven plasmids were first tested in human embryonic kidney (HEK) cells by 
transfection, to ensure that cloning of the GAD67 and CCK promoters allowed transcription of the 
downstream opsin-fluorophore construct (Supplementary Fig. 2). Transduction of viral particles 
was then assessed in neuronal cultures. 
CCK- and GAD67-driven NpHR-EYFP expresses in ganglionic eminence neuronal cultures
We transduced neuronal cultures from the ganglionic eminence (GE; kindly provided by A. Zito and
W. Andrews, Parnavelas lab, UCL) as a culture model rich in inhibitory cells (Fig.1). In rodents, 
GAD67 mRNA is expressed from embryonic day 10.5 (E10.5) [32], CCK mRNA from E12.5  [33]. 
E14 cultures were transduced at days 5-7 in vitro with 106 copies/ml LVV per well and imaged two 
weeks later. Fluorescence was visible for LV-GAD67-NpHR2.0-EYFP and LV-CCK-NpHR2.0-
EYFP: ~90 % of cells expressing LV-CCK-NpHR2.0-EYFP also stained for anti-CCK antibody 
(19/21 cells, 4 visual fields (VFs)). 40% of LV-GAD67-NpHR2.0-EYFP expressing neurons were 
also anti-GABA antibody positive(+) (73/181 cells, 4 VFs). Our culture data suggests that LV-CCK-
NpHR2.0-EYFP may be useful in targeting CCK+ interneurons in GE cultures. 
GAD and CCK driven opsin vectors are not specific for interneurons in vivo
Fluorescence was visible in unstained, acutely sliced sections of rodent brain injected with LVV 
encoding NpHR2.0-EYFP under either Camk2a, GAD67 or CCK-promoters and AAV-eNPAC 
(Table 1, Supplementary Fig. 3, Supplementary Table 1), the highest achievable viral titre for each 
construct was used (ranging from 3 – 5 x 108 copies ml for LVV and 1012 vg/ml for AVV) in both 
cortex and hippocampus. Conversely, LV vectors expressing ChR2-mCherry under the Camk2a, 
GAD67 and CCK promoters were only visible on stained sections (Fig. 2 and 4). This may have 
been due to low expression levels, or to protein misfolding, allowing ChR2-mCherry to become 
visible only after immunostaining.
The vector LV-GAD67-ChR2-mCherry  was not selective for interneurons in CA1 and CA3: only 
7.5% (5/67) of cells expressing LV-GAD67-ChR2-mCherry were also GABA positive (Fig.2a-d), 
whilst of all GABA+ interneurons, only 2.6% (5/193) expressed LV-GAD67-ChR2-mCherry. 2.4% 
(27/1121) of pyramidal cells also expressed the transgene (Fig.2e). 
In a separate set of experiments we tested the vector LV-GAD67-NpHR2.0-EYFP:  82% (91/110) 
of LV-GAD67-NpHR2.0-EYFP expressing neurons were positive for Camk2a (Fig. 3a-c, g), 21% 
(43/207) were GABA+ (Fig. 3d-f, h). Approximately 15% (43/279) of GABA+ interneurons 
expressed  LV-GAD67-NpHR2.0-EYFP.
LV-CCK-ChR2-mCherry stained very few neurons in the hippocampal pyramidal layer, and 
expression was difficult to find by microscopy despite repeated experiments. Eight LV-CCK-ChR2-
mCherry - positive neurons were identified in four visual fields, seven of which co-stained with anti-
GABA antibodies (Fig. 4a-d). The difficulty in visualizing ChR2-mCherry in vivo was thought to be 
due to either low expression levels or to opsin-fluorophore misfolding, as the antibodies targeted to
mCherry demonstrated that the protein had been expressed. 
26% (9/34) of LV-CCK-NpHR2.0-EYFP expressing neurons were positive for GABA antibody. LV-
CCK-NpHR2.0-EYFP stained 2% (2/98) of anti-Camk2a (Fig.5a-c, g), and 47% (9/19) of anti-
GABA (Fig.5d-f, h) positive neurons. 
Expression volumes of GAD/CCK driven constructs are small
The total volume of viral vector expression was calculated for a whole injection area per vector by 
summing the fluorescent volume of each slice (area exhibiting strongly fluorescent neurons under 
5x or 10x magnification multiplied with thickness of the slice). In the hippocampus, expression 
volumes of GAD67 promoter driven constructs were larger than those of CCK-driven vectors. The 
control vector AAV-eNPAC achieved the largest expression volumes (Fig.6 and Table 1). In the 
cortex, expression volumes were again largest for AVV injected animals (Supp. Fig. 3 and Supp. 
Table  1). 
Discussion
GAD67 Promoter-driven Opsins
Expression of the GAD67 promoter-driven opsin constructs was not specific for interneurons both 
in cultures and slices. The GAD67 promoter construct used in our vectors contains 3.7 kb of 5’ 
upstream sequences (’short’ GAD67 promoter [21, 22]), containing the first intron and part of the 
second exon of the GAD67 promoter. This ’short’ promoter has been previously used to target 
GABAergic interneurons in the nucleus of solitary tract in organotypic slice cultures [22]. If 
increasingly longer 5’ upstream regulatory sequences are included in the GAD67 promoter 
construct [21], the expression of reporter genes becomes more specific. However, transgenic 
mouse lines containing up to 7 kb of 5’ upstream sequences (’medium’ and ’long’ promoters) of the
GAD67 promoter still showed variable staining of hippocampal interneurons [21], as well as ectopic
expression in hippocampal pyramidal neurons that express low levels of GAD mRNA [34]. Only the
longest construct (9 kb of 5’ upstream sequences) correctly labelled cerebellar Purkinje cells, whilst
still showing patterns of mixed correct and ectopic expression both in hippocampus and cortex 
[21]. In concordance with these observations, the ’short’ GAD67 promoter we used, may contain all
regulatory sequences for correct expression in brain regions of high GABA content, which develop 
early [21], but may not be specific for the targeting of interneurons in the hippocampus or cortex. 
CCK Promoter-driven Opsins
In cultures from the ganglionic eminence Nearly all cells expressing CCK-driven NpHR-EYFP were
positive for CCK, although only a limited number of cells was tested. In vivo, however, CCK-driven 
expression levels were small and less specific, making these vectors unsuitable for 
electrophysiology applications. The CCK promoter (gift of K. Ressler) has been used to label 
interneurons of the hippocampus and the basolateral amygdala [23, 24], which were 
counterstained with CCK-mRNA in situ hybridization techniques. In our experiments, LV-CCK-
NpHR2.0-EYFP achieved good expression in the polymorphic layer of the dentate gyrus, but 
stained only few cells in CA1 which were undoubtedly pyramidal, both in their morphology and 
antibody staining pattern (Fig. 3d). One possible explanation for the discrepancy of these results  
may be that neurons expressing CCK-mRNA are different or more numerous than those also 
expressing the CCK octopeptide, e.g. CCK-mRNA is found in the somata of neurons in many brain
regions including CA3 pyramidal cells [35]. Staining for the CCK peptide, rather than using in situ 
hybridization, may be a more specific way to detect expression of the actual neurotransmitter. 
Choice of Viral Vectors
AVVs serotype 2 and 5 are known to transduce mostly neurons [36] and our opsins delivered with 
AVV were strongly expressed within the hippocampus and cortex, and in a larger volume than 
constructs delivered with lentiviruses. AVV preparations are known to achieve higher titres than 
LV-vector preparations, and due to their smaller size (~ 25nm) [36], AAV vector particles (size 
~100 nm) spread over a larger volume than LV-vectors.  A diffuse spread of vector has the 
additional advantage that a single injection may be sufficient for experimental or future therapeutic 
purposes. The motivation to use lentiviral vectors, was their large transgene capacity (8-10 kb in 
LV vs 4.5 kb in AAV), which allowed us to clone the relatively large GAD67 and CCK promoter 
sequences (3.5 and ~3 kb, respectively) ahead of the opsin-fluorophore constructs. An alternative 
approach may involve splitting large transgenes onto 2 complementary AAVs, but the techniques 
are complex, and the success rate in generating the constructs may be lower. A further 
disadvantage of AVVs is their potential for inducing neutralizing antibodies. Conversely, LVVs are 
relatively invisible to the immune system, as viral proteins are not expressed on the surface of 
transduced cells. This is a clear advantage if considering viral vectors as future therapeutic tools. 
Conclusion
The ability to study and influence the activity of excitatory and inhibitory interneurons separately, is 
one of the main goals of modern neuroscience and a requirement for future gene therapy of 
nervous system diseases. Opsins are ideal candidates to accomplish this task, but targeting 
separate neuronal populations with GAD67 and CCK promoter-carrying vectors is not possible in 
their current form. More work is required to understand, at the molecular level, which regulatory 
elements and epigenetic mechanisms determine promoter function and how cell-type specific 
expression is achieved in inhibitory interneurons. 
Figure Legends
Figure 1 CCK- and GAD67-driven opsins express in ganglionic eminence neuronal cultures. 
LV-CCK-NpHR2.0-EYFP (a-c and g): Approximately 90% (19/21) of LV-CCK-NpHR2.0-EYFP 
expressing neurons (a, in green) also stain for anti-CCK antibody (b, in red). Overlay in c. Arrows 
depict examples of colocalizing neurons, arrowheads non-colocalizing neurons. LV-GAD67-
NpHR2.0-EYFP (d-f and h): 40% (73/181) of LV-GAD67-NpHR2.0-EYFP expressing neurons (d, 
in green) also stain for GABA-antibody (e, in red). Overlay in f. Arrows and arrowheads used as 
above. (Antibody (Ab), positive (+).) 
Figure 2 Immunofluorescence study of LV-GAD67-ChR2-mCherry expression in 
hippocampus and cortex. (a) LV-GAD67-ChR2-mCherry-expressing neurons (in red, 
arrowheads) do not colocalize with (b) anti-GABA positive interneurons (in green). (c) overlay (with
DAPI). Experiments with anti-GABA and anti-CaMKIIa antibodies were not performed in the same 
slices. (d) 7.5% of vector expressing cells (5/67) were positive for GABA (n=3 slices, 20 VF 
counted, 1 animal, total number of cells in brackets). The remaining vector expressing neurons 
may have been non GABA-ergic neurons, e.g. excitatory principal neurons, cholinergic non-
GABAergic non-principal cells, granule cells.(e) 30% (27/91) of vector expressing cells were 
excitatory neurons and stained with Camk2a antibody (n=4 slices, 22 VF counted, 3 animals, total 
number of cells in brackets). The remainder of vector expressing cells may have been GABAergic 
neurons, cholinergic non-GABAergic non-principal cells, principal cells expressing a different 
CaMKII isoform,  granule cells or neurogliaform cells. Whilst the % of positive neurons will depend 
on the viral titre, we used the highest titre achievable in our hands, which resulted in non-specific 
staining. Lower titres were not tested as they were predicted to achieve even lower expression. 
The scale bar is 25 µm for all images. Stratum radiatum (rad.), pyramidale (pyr.; dotted lines) and 
oriens (or); positive (+); visual field (VF).
Figure 3 Colocalization of LV-GAD67-NpHR2.0-EYFP with Camk2a or GABA in 
hippocampus. (a-c, g) LV-GAD67-NpHR2.0-EYFP-expressing neurons in green, anti-Camk2a 
positive pyramidal cells in red and overlay with DAPI to visualize cell nuclei. Arrows point to 
colocalizing, arrowheads to non-colocalizing neurons. 82% (91/110) of LV-GAD67-NpHR2.0-EYFP
expressing neurons are pyramidal cells (12 VF, 2 animals, total number of cells in brackets). (d-f, 
h) LV-GAD67-NpHR2.0-EYFP-expressing neurons in green, anti-GABA positive interneurons in 
red and overlay with DAPI (23 VF, 3 animals, total number of cells in brackets). Arrows and 
arrowheads used as above. The scale bar is 25 µm for all images. Stratum radiatum (rad.), 
pyramidale (pyr.; dotted lines) and oriens (or); visual field (VF).
Figure 4 Immunofluorescence and colocalization of LV-CCK-ChR2-mCherry in stratum 
oriens (or). (a) LV-CCK-ChR2-mCherry-expressing neurons in red (arrows), (b) anti-GABA 
positive cells in green and (c) overlay with DAPI to visualize cell nuclei. (Arrows indicate 
colocalizing, arrowheads not co-localizing cells). (d) 7/14 anti-GABA antibody stained neurons also
expressed LV-CCK-ChR2-mCherry (4 VFs, 1 animal). 7/8 LV-CCK-ChR2-mCherry positive cells 
stained for anti-GABA antibody. Numbers of cells counted in brackets. The scale bar is 25 µm for 
all images; visual field (VF).
Figure 5 Colocalization study of LV-CCK-NpHR2.0-EYFP in hippocampus. (a-c, g) LV-CCK-
NpHR2.0-EYFP-expressing neurons in green, anti-Camk2a positive pyramidal cells in red and 
overlay with DAPI to visualize cell nuclei (n=7 VF, 3 slices, 2 animals). Arrowheads points to LV-
CCK-NpHR2.0-EYFP-expressing neurons, which do not colocalize with anti-Camk2a+ cells. (d-f, 
h) LV-CCK-NpHR2.0-EYFP-expressing neurons in green, anti-GABA positive interneurons in red 
and overlay with DAPI (n=3 VF counted from 2 animals). Arrowheads points to LV-CCK-NpHR2.0-
EYFP-expressing neurons, which do not colocalize with anti-GABA+cells. Numbers of cells 
counted in brackets. Stratum radiatum (rad.), pyramidale (pyr.; dotted lines) and oriens (or); visual 
field (VF).
Figure 6 Comparison of expression levels in hippocampus. Fluorescence micrographs 
showing extent of expression in hippocampus injected with 1.5 μl of either (a) LV-CCK-NpHR2.0-
EYFP, (b) LV-GAD67-NpHR2.0-EYFP (both 10x magnification), or (c) 1 μl AAV-eNPAC (5x 
magnification). Slices were counterstained with anti-GFP antibodies and AF 488 secondary 
antibodies to amplify the GFP signal; Stratum radiatum (rad.), pyramidale (pyr.; dotted lines) and 
oriens (or); visual field (VF).
Table 1 Comparison of expression in hippocampal slices injected with LVVs carrying 
different promoters and LVV vs. AVV
Supplementary Figure Legends
S1 Immunohistochemistry on control sections 
Fluorescent micrographs from GAD67-GFP mice used as positive controls for anti-GAD67, anti-
CCK and anti-Camk2a antibodies. (a), (d), (g) Interneurons expressing GFP under the GAD67 
promoter. (b) Anti-Camk2a stains neurons in the pyramidal layer of the hippocampus (n = 97) and 
none of the GFP+ neurons (n = 23; arrowheads). (c) shows overlay images of the green (a), red 
(b) and blue (DAPI) channels. (e) All GABA-antibody stained neurons (n = 14) expressed green 
fluorescence (arrows). (f) showing overlay images of (d), (e) and the blue (DAPI) channel. (h) 
CCK-antibody stained neurons in red (i) overlay image: 80% (7/9) of CCK+ neurons (red) 
expressed GFP (green) . One third of GFP expressing interneurons (green) also stained for CCK-
antibody (9/27; arrows). Stratum radiatum (rad.), pyramidale (pyr.; dotted lines) and oriens (or). 
S2 Transfected HEK cells express transgene 
Cloned lentiviral constructs and assessment of promoter activity in vitro. (a-c) Left panels: 
schematic of the viral vector; right panels: fluorescence micrographs of transfected HEK cells. 
Micrograph a2 and b2 were taken with a different filter setting. 
S3 Expression volumes in cortex 
Comparison of expression levels in cortex. Fluorescence Micrographs at 10x magnification 
obtained from cortex of animals injected with (a) LV-CCK-NpHR2.0-EYFP, (b) LV-Camk2a-
NpHR2.0-EYFP and at (c) 5x magnification showing expression of AAV-eNPAC. Continuous line 
denotes the area of fluorescence, dashed line the pial surface. Slices were counterstained with 
anti-GFP antibodies and AF 488 secondaries to amplify the GFP signal; injection volume 1–1.25 
μl.  
S Table 1 Comparison of expression in cortical slices injected with LVV vs. AVV.
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Viral Titre 10  copies/ml⁸ 10  copies/ml⁸ 2 x 1012 vg/ml
Injection 
Volume 1.5 µl 1.5 µl 1 µl
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Viral Titre 10  copies/ml⁸ 2 x 1012  vg/ml
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Volume 1.25 µl 1 µl
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Figure 5: Colocalization study of LV-CCK-NpHR2.0-EYFP in hippocampus.
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Figure 6: Comparison of expression levels in hippocampus.
Table 1: Comparison of expression in hippocampal slices injected with LVs






























































GAD promoter NpHR  GFP WPRE LTR
LTR
Psi+ RRE
Camk2a NpHR  GFP WPRE LTR
LTR
Psi+ RRE
Camk2a ChR2 mCherry WPRE LTR
LTR
Psi+ RRE
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S2 Transfected HEK cells express transgene
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S3 Expression volumes in Cortex




Viral Titre 108 TU/ml 2 x 10 12 TU/ml
Injection
Volume 1.25µl 1µl
Expression
Volume 0.04mm3 0.09mm3
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